Abstract:Introduction Gastric cancer (GC) is the fourth most common cancer and the third-leading cause of cancer-related deaths worldwide. Despite certain advances in chemotherapy regimens and targeted therapies, the 5 year survival of patients with advanced GC is disappointing. The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC) refractory to two or more lines of prior systemic chemotherapies. However, a dose reduction or treatment interruption is required to prevent apatinib toxicity such as hand-foot skin reaction (HFSR), proteinuria, and hypertension. In addition, suitable biomarkers are not accessible for identifying the patients who are most likely to benefit from apatinib. Therefore, predictive biomarkers are urgently needed to reduce toxicity and identify patients that will benefit from apatinib treatment. Material and methods Clonogenic assay, cytotoxicity assay, apoptosis assay, qRT-PCR, western blot were conducted in GC cells to evaluate the effectiveness of apatinib in vitro. Confocal microscopy assay was peformed to examine apatinib-induced autophagic flux in GC cells. Transmission electron microscopy assay was conducted to show the formation of autophagic vesicles. Xenograft models in mice were conducted and six tumour tissues were sent for miRNA-seq and circRNA-seq. Sanger sequencing was applied to determine the full length of the amplification products. Results and discussions In this study, we found that apatinib inhibited the growth of GC cells and xenograft tumours. Apatinib promoted autophagy activation via upregulation of ATG7 expression, and autophagy inhibition enhanced apatinib-induced apoptosis. With miRNA-seq and circRNA-seq analyses of GC xenograft models, we demonstrated that circRNA004582 functioned as an endogenous sponge for miR-3657 to inhibit its activity and further upregulate ATG7 expression. Silencing of circRNA004582 inhibited apatinib-induced autophagy, which was rescued by miR-3657. Moreover, knockdown of circRNA004582 promoted apatinib-induced apoptosis in GC cells. These findings provided the first evidence that the circRNA004582-miR-3657-ATG7 axis mediates a regulatory pathway critical for the regulation of autophagy and apatinib sensitivity in GC cells and xenografts. Conclusion In conclusion, specific blockage of circRNA004582 may be a potential therapeutic target for autophagy inhibition in the context of apatinib treatment in human GC. Prospective clinical studies are warranted to examine these biomarkers.

Mitochondrial ROS Accumulation Inhibiting JAK2/STAT3 Pathway is a Critical Modulator of CYT997-induced Autophagy and Apoptosis in Gastric Cancer

Cryptotanshinone Potentiates the Antitumor Effects of Doxorubicin on Gastric Cancer Cells Via Inhibition of STAT3 Activity.

HJC0152, a Novel STAT3 Inhibitor with Promising Anti-Tumor Effect in Gastric Cancer

MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

Blocking Autophagy Enhances the Apoptotic Effect of 18Β-Glycyrrhetinic Acid on Human Sarcoma Cells Via Endoplasmic Reticulum Stress and JNK Activation

CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma

Celecoxib Regulates Apoptosis And Autophagy Via The Pi3k/Akt Signaling Pathway In Sgc-7901 Gastric Cancer Cells

α-Tocopheryl succinate-induced apoptosis in human gastric cancer cells is modulated by ERK1/2 and c-Jun N-terminal kinase in a biphasic manner

Inhibition of Autophagy Promotes Metastasis and Glycolysis by Inducing ROS in Gastric Cancer Cells.

AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer

Jaceosidin induces apoptosis and inhibits migration in AGS gastric cancer cells by regulating ROS-mediated signaling pathways

Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway

PO-071 Silencing of Circrna004582 Sensitises Gastric Cancer Cells to APATINIB Via Modulating Autophagy by Targeting Mir-3657 and ATG7

A Combined Proteomics and Metabolomics Profiling of Gastric Cardia Cancer Reveals Characteristic Dysregulations in Glucose Metabolism

Dual PI3K/mTOR Inhibitor PF-04979064 Regulates Tumor Growth in Gastric Cancer and Enhances Drug Sensitivity of Gastric Cancer Cells to 5-FU

Protective Macroautophagy is Involved in Vitamin E Succinate Effects on Human Gastric Carcinoma Cell Line Sgc-7901 by Inhibiting Mtor Axis Phosphorylation

Crosstalk of mTOR/PKM2 and STAT3/c-Myc signaling pathways regulate the energy metabolism and acidic microenvironment of gastric cancer.

Class I Phosphatidylinositol 3-Kinase Inhibitor LY294002 Activates Autophagy and Induces Apoptosis Through P53 Pathway in Gastric Cancer Cell Line SGC7901

ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin

Nrf2: A critical participant in regulation of apoptosis, ferroptosis, and autophagy in gastric cancer

Thymoquinone induces apoptosis and protective autophagy in gastric cancer cells by inhibiting the PI3K/Akt/mTOR pathway